First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
No fewer than four ADCs with this target start human testing.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The company is set to start a phase 2/3 trial this month.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
The group will start a pivotal trial of samuraciclib following promising second-line results.
